BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $65
CG Oncology Is Maintained at Buy by B of A Securities
BofA Securities Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $65
With 52% Institutional Ownership, CG Oncology, Inc. (NASDAQ:CGON) Is a Favorite Amongst the Big Guns
We Think CG Oncology (NASDAQ:CGON) Can Afford To Drive Business Growth
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
Buy Rating Affirmed for CG Oncology Amid Strong Clinical Performance and Promising Market Prospects
CG Oncology Price Target Announced at $66.00/Share by RBC Capital
RBC Capital Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $66
RBC Capital analyst Gregory Renza initiates coverage on $CG Oncology(CGON.US)$ with a buy rating, and sets the target price at $66.According to TipRanks data, the analyst has a success rate of 46.5%
RBC Initiates CG Oncology at Outperform, Speculative Risk With $66 Price Target
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
H.C. Wainwright analyst Andres Y. Maldonado maintains $CG Oncology(CGON.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate of 50.8
Buy Rating Justified for CG Oncology's Cretostimogene Due to Superior Safety Profile and Competitive Efficacy
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Goldman Sachs Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $52
Goldman Sachs analyst Chris Shibutani initiates coverage on $CG Oncology(CGON.US)$ with a buy rating, and sets the target price at $52.According to TipRanks data, the analyst has a success rate of 45.
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $86
LifeSci Capital analyst Sam Slutsky maintains $CG Oncology(CGON.US)$ with a buy rating, and maintains the target price at $86.According to TipRanks data, the analyst has a success rate of 46.0% and
Buy Rating Affirmed for CG Oncology Amid Competitive Landscape and Strong Clinical Results
CG Oncology Insider Sold Shares Worth $23,000,089, According to a Recent SEC Filing
CG Oncology(CGON.US) Director Sells US$23 Million in Common Stock
$CG Oncology(CGON.US)$ Director Song Hong Fang sold 650.46K shares of common stock on Aug 29, 2024 at an average price of $35.36 for a total value of $23 million.Source: Announcement What is
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference